Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -7% Improvement Relative Risk Death or respiratory sup.. 30% c19early.org/e Sisinni et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 984 patients in Italy Lower death/intubation with aspirin (p=0.012) Sisinni et al., Int. J. Cardiology, doi:10.1016/j.ijcard.2021.09.058 Favors aspirin Favors control
Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
Sisinni et al., International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058
Sisinni et al., Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The.., International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 984 COVID-19 patients, 253 taking aspirin prior to admission, showing lower risk of respiratory support upgrade with treatment.
risk of death, 7.1% higher, RR 1.07, p = 0.65, treatment 93 of 253 (36.8%), control 251 of 731 (34.3%).
risk of death or respiratory support upgrade, 30.3% lower, RR 0.70, p = 0.01, treatment 253, control 731, multivariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sisinni et al., 4 Oct 2021, retrospective, Italy, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Journal Pre-proof Pre-admission acetylsalicylic acid therapy and impact on inhospital outcome in COVID-19 patients: The ASA-CARE study Antonio Sisinni, Luca Rossi, Antonio Battista, Enrico Poletti, Federica Battista, Rosa Alessia Battista, Alessandro Malagoli, Andrea Biagi, Alessia Zanni, Concetta Sticozzi, Greta Comastri, Massimiliano M. Marrocco-Trischitta, Alberto Monello, Alberto Margonato, Francesco Bandera, Pasquale Vergara, Marco Guazzi, Cosmo Godino PII: S0167-5273(21)01499-6 DOI: https://doi.org/10.1016/j.ijcard.2021.09.058 Reference: IJCA 29821 To appear in: International Journal of Cardiology Received date: 4 July 2021 Revised date: 26 September 2021 Accepted date: 28 September 2021 Please cite this article as: A. Sisinni, L. Rossi, A. Battista, et al., Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study, International Journal of Cardiology (2021), https://doi.org/10.1016/ j.ijcard.2021.09.058 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier B.V. Journal Pre-proof Pre-admission Acetylsalicylic Acid Therapy and Impact on In-hospital Outcome in COVID-19 patients: the ASA-CARE study. Antonio Sisinni,1 MD, Luca Rossi,2 MD, Antonio Battista,3 MD, Enrico Poletti,4 MD, Federica Battista,5 MD, Rosa Alessia Battista,6 MD, Alessandro Malagoli,7 MD, Andrea Biagi,8 MD, Alessia Zanni,9 MD, Concetta Sticozzi,10 MD, Greta Comastri,11 MD, Massimiliano M Marrocco-Trischitta,12 MD, Alberto Monello,13 MD, Alberto Margonato,14 MD, Francesco Bandera,15 MD, Pasquale Vergara,16 MD, Marco Guazzi*,17 MD, Cosmo Godino*,18 MD. 1 Jo ur na lP re -p ro of Cardiology Unit, IRCCS Policlinico San Donato, Milan, Italy. Università degli studi di Milano, Milan, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 2 Division of Cardiology, Cardiovascular and Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 3 Emergency Department, Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 4 Cardiology Unit, IRCCS Policlinico San Donato, Milan, Italy. Università degli studi di Milano, Milan, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 5 Università degli studi di Pavia, Pavia, Italy. This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. 6 i i Vita-Salute San Raffaele, Milano, Italy. This author takes..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit